Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :
MONDAY, FEBRUARY 23, 2026
08:00 - 09:00
REGISTRATION AND MORNING REFRESHMENTS
09:00 - 09:10
OPENING ADDRESS
09:10 - 09:35
INJECTING INNOVATION: HUMAN AND SCIENTIFIC REALITIES IN LARGE-VOLUME SUBCUTANEOUS DRUG DELIVERY
Mehul Desai
Enable Injections, Inc.

Mehul Desai

Enable Injections, Inc.

  • Reframing industry views on large-volume SC limits and how they can stifle innovation
  • Examining clinician perspectives on large-volume SC options and bioavailability impacts
  • Navigating formulation challenges in large-volume SC delivery that raise time, costs, and risks
09:35 - 09:40
Q&A SESSION ON LARGE-VOLUME SUBCUTANEOUS DRUG DELIVERY
09:40 - 10:05
SUBCUTANEOUS DELIVERY OF BIOLOGICS AND ADCS: LESSONS, PATHWAYS, AND DEVICES
Charles Theuer
Halozyme

Charles Theuer

Halozyme

  • Utilizing subcutaneous Ab administration experience to guide delivery strategies of ADCs at scale
  • Documenting clinical development pathways for approval of subcutaneously delivered biologics
  • Permitting rapid 10 mL SC dosing using hyaluronidase with high-volume autoinjectors
10:05 - 10:10
Q&A SESSION ON SUBCUTANEOUS DELIVERY OF BIOLOGICS & ADCS
10:10 - 10:35
LEAVING THE ICE AGE – STABILIZATION OF VIRAL VECTORS TO CIRCUMVENT FROZEN STORAGE
Cornelius Pompe
Leukocare AG

Cornelius Pompe

Leukocare AG

  • Overcoming frozen storage barriers hindering reliable and scalable viral vector supply chains
  • Applying an integrated analytical toolkit with data science to identify stability determinants
  • Showcasing case studies enabling robust non-frozen formulations for clinical and commercial use
10:35 - 10:40
Q&A SESSION ON NON-FROZEN STABILIZATION OF VIRAL VECTORS WITH ANALYTICS
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON DRUG DELIVERY
11:30 - 11:55
BIOAVAILABILITY ENHANCEMENT STRATEGIES FOR TARGETED PROTEIN DEGRADERS
Rebecca Coutts
PCI Pharma Services

Rebecca Coutts

PCI Pharma Services

  • Catalyzing oral TPD bioavailability with hot melt extrusion, spray drying, and nanotechnology
  • Partnering via product-first, platform-agnostic teams for integrated end-to-end solutions
  • Centralizing proof of concept through clinical supply to streamline communication and continuity
11:55 - 12:00
Q&A SESSION ON ORAL BIOAVAILABILITY OF TARGETED PROTEIN DEGRADERS
12:00 - 12:25
ENABLING ORAL AND PARENTERAL DELIVERY OF GLP-1 PEPTIDE FROM BIOPHYSICAL AND MOLECULAR INVESTIGATIONS
Jing Ling
Merck

Jing Ling

Merck

  • Understanding how permeation enhancers improve oral GLP-1 peptide bioavailability
  • Analyzing peptide-excipient and silicone oil interactions to enable stable combination products
  • Extending biophysical insights to parenteral formats to strengthen stability and performance
12:25 - 12:30
Q&A SESSION ON ORAL AND PARENTERAL DELIVERY OF GLP-1
12:30 - 13:30
NETWORKING LUNCH & VISITING THE DRUG DELIVERY EXHIBITION
13:30 - 13:55
CUSTOM POLOXAMERS FOR ENHANCED FORMULATION AND DELIVERY OF APIs
Mahsa Mohiti-Asli
BASF

Mahsa Mohiti-Asli

BASF

  • Introducing BASF’s GMP Solution Center in Wyandotte and its custom poloxamer manufacturing capabilities
  • Tailoring poloxamer grades to enhance API solubility and improve delivery in challenging formulations
  • Presenting case examples of custom poloxamers developed to address key industry challenges
13:55 - 14:00
Q&A SESSION ON CUSTOM POLOXAMERS FOR APIs
14:00 - 14:25
ACCELERATING DEVELOPMENT OF ORAL SOLIDS: FROM BENCH TO BEDSIDE
Heena Maithania
Frontage Laboratories, Inc.

Heena Maithania

Frontage Laboratories, Inc.

  • Implementing API in capsule microdosing with Xcelodose 600S for rapid early capsule development
  • Enhancing dissolution of poorly soluble compounds using dry granulation case studies
  • Standardizing flow, particle size, hygroscopicity, and blend uniformity across batches
14:25 - 14:30
Q&A SESSION ON ORAL SOLIDS DEVELOPMENT
14:30 - 14:55
EMERGING EXCIPIENT TRENDS INFLUENCING THE FUTURE OF PHARMACEUTICALS
Manish Ghimire
IMCD Group

Manish Ghimire

IMCD Group

  • Surveying excipients that enable advanced delivery performance in complex formulations
  • Embedding sustainability through smarter ingredient selection and improved manufacturing processes
  • Elevating patient-friendly dosage forms that improve experience and adherence across populations
14:55 - 15:00
Q&A SESSION ON EMERGING EXCIPIENT TRENDS IN PHARMA
15:00 - 15:30
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:30 - 15:55
INNOVATIVE DELIVERY STRATEGIES FOR INSOLUBLE AND NUCLEOSIDE-BASED THERAPEUTICS: BRIDGING SMALL MOLECULES AND RNA DRUGS
James Carroll
RNA NanoBiotics, Inc.

James Carroll

RNA NanoBiotics, Inc.

  • Formulating insoluble oncology agents like SN-38 via nano and conjugate approaches for better uptake
  • Co-delivering RNA therapeutics with nucleoside analogs to improve targeting and reduce toxicity
  • Streamlining translation via nanoparticles, conjugates, and 505(b)(2) pathways for faster trials
15:55 - 16:00
Q&A SESSION ON STRATEGIES FOR DELIVERY OF INSOLUBLE AGENTS
16:00 - 16:25
DECISION-MAKING FRAMEWORKS FOR ASSESSING MOLECULAR PROPERTIES TO GUIDE BIOAVAILABILITY ENHANCING TECHNOLOGY SELECTION
Tyler Clikeman
Catalent

Tyler Clikeman

Catalent

  • Guiding technology choice for amorphous dispersions, lipid systems, cyclodextrins, and micronization
  • Integrating empirical and mechanistic models with dissolution tools to predict bioavailability
  • Diagnosing rate-limiting absorption for a beyond-rule-of-five PROTAC compound
  • Avoiding improper dosing of enhanced formulations to reduce risk and variability
16:25 - 16:30
Q&A SESSION ON BIOAVAILABILITY ENHANCING TECHNOLOGIES
16:30 - 16:55
GO WITH THE NASAL FLOW: HOW A NOSE PLUG COULD REVOLUTIONIZE TODAY'S SUBOPTIMAL NASAL DELIVERY METHODS
Peter Åhnblad
Hogne AB

Peter Åhnblad

Hogne AB

  • Resolving core limitations of today’s nasal delivery to improve dosing, coverage, and comfort
  • Converting the nose into a controlled delivery gateway with an ergonomic, easy-to-use nose plug
  • Reimagining nasal flow using nose plugs to enable next generation intranasal delivery devices
16:55 - 17:00
Q&A SESSION ON FLOW-DIRECTED NASAL DELIVERY WITH NOSE PLUGS
17:00 - 18:00
NETWORKING DRINKS RECEPTION
Day 2 :
TUESDAY, FEBRUARY 24, 2026
08:30 - 09:00
MORNING REFRESHMENTS
09:00 - 09:10
OPENING ADDRESS
09:10 - 09:35
TRACKING THE FATE OF BIODEGRADABLE LNPS IN VIVO
Syed Reza
NOF AMERICA CORPORATION

Syed Reza

NOF AMERICA CORPORATION

  • Elucidating how highly biodegradable lipids can improve tolerability and therapeutic potency
  • Overcoming in vivo tracking hurdles from labile lipids and metabolites unsuitable for detection
  • Measuring metabolism and excretion with a bioanalytical approach that resolves detection gaps
09:35 - 09:40
Q&A SESSION ON IN VIVO LNP TRACKING AND BIOANALYTICS
09:40 - 10:05
MAKING BIOLOGICS AND NANOPARTICLES INTO MAGIC BULLETS PENETRATING THE BARRIER TO PRECISION IMAGING AND THERAPY
Jan Schnitzer
Proteogenomics Research Institute for Systems Medicine

Jan Schnitzer

Proteogenomics Research Institute for Systems Medicine

  • Uncovering why passive transvascular delivery hinders small molecules, antibodies, and nanoparticles
  • Mapping endothelial barrier targets across organs to guide precise tissue entry and penetration
  • Creating "magic bullets" via caveolae immunotargeting to concentrate >50% of dose in one tissue
10:05 - 10:10
Q&A SESSION ON DRUG DELIVERY ACROSS BLOOD–TISSUE BARRIERS
10:10 - 10:35
USING XERIS’ XERIJECT FORMULATION PLATFORM FOR LARGE MOLECULE PARENTERAL DRUG DELIVERY
Peter Knauer
Xeris Pharmaceuticals

Peter Knauer

Xeris Pharmaceuticals

  • Outlining the XeriJect platform for high-concentration large-molecule parenteral formulations
  • Profiling device compatibility for XeriJect formulations, including autoinjectors for ease of use
  • Displaying nonclinical delivery and stability data that demonstrate platform performance
10:35 - 10:40
Q&A SESSION ON XERIJECT FORMULATION PLATFORM
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:25
ADVANCEMENTS IN GLOBAL DRUG DEVELOPMENT
Gurpreet Singh
IQVIA

Gurpreet Singh

IQVIA

  • Prioritizing patient safety as the foundation for reliable, ethical, efficient development
  • Harnessing real world evidence to inform decisions, reduce risk, and speed approvals globally
  • Transforming development with digital and AI technologies that shape future workflows
11:25 - 11:30
Q&A SESSION ON THE FUTURE OF DRUG DEVELOPMENT
11:30 - 11:55
FROM MOLECULE TO MARKET: ALGORITHM-BASED TOOLS IN STREAMLINING DRUG PRODUCT DEVELOPMENT
Damien Bellos
BASF

Damien Bellos

BASF

  • Leveraging algorithm-based platforms for faster, smarter, predictive formulation strategies
  • Exemplifying BASF’s ZoomLab for virtual screening and data-driven excipient–API design
  • Accelerating development timelines while reducing complexity via precision decision support
11:55 - 12:00
Q&A SESSION ON ALGORITHM-BASED FORMULATION DEVELOPMENT
12:00 - 12:25
ODC™: A NAKED, TARGETED OLIGO MODALITY FOR PRECISION DELIVERY AND BBB-CROSSING RNA/DNA THERAPEUTICS
Zoya Gluzman-Poltorak
Forta Bio, Inc.

Zoya Gluzman-Poltorak

Forta Bio, Inc.

  • Defining ODC as a naked, ligand-targeted oligonucleotide class designed for precision delivery
  • Integrating TERT-activated cytotoxicity and programmable immunomodulation within the ODC platform
  • Facilitating cell-specific uptake via CpG or aptamer ligands without vectors or encapsulation
  • Crossing the BBB in preclinical glioma with aptamer-guided ODC and scalable IV CNS delivery
12:25 - 12:30
Q&A SESSION ON OLIGONUCLEOTIDE-DEPENDENT CYTOTOXICITY
12:30 - 13:30
NETWORKING LUNCH & VISITING THE DRUG DELIVERY EXHIBITION
13:30 - 13:55
INSTAPILL ®: LYOPHILIZED ODT PLATFORM FOR WATER-FREE ORAL DELIVERY
Keith Dodson
InstaPill Private Limited

Keith Dodson

InstaPill Private Limited

  • Emphasizing instant disintegration of InstaPill ODTs for water-free dosing and better compliance
  • Allowing pre-gastric uptake to improve bioavailability and reduce first-pass metabolism
  • Ensuring taste masking, protein/peptide stability, and low excipients for pediatrics
13:55 - 14:00
Q&A SESSION ON LYOPHILIZED ODTS AND WATER-FREE DELIVERY
14:00 - 14:25
PIONEERING BIFUNCTIONAL SMALL MOLECULES IN ONCOLOGY AND BEYOND
Mehran F. Moghaddam
OROX Biosciences, Inc.

Mehran F. Moghaddam

OROX Biosciences, Inc.

  • Addressing unmet needs in oncology with bifunctional small molecules and focused development strategies
  • Unveiling IND-ready OX-001 with a non-immunosuppressive, dual-action anticancer profile
  • Combining single-agent efficacy with therapeutic synergy while sparing healthy tissues with OX-001
14:25 - 14:30
Q&A SESSION ON BIFUNCTIONAL OX-001 PROFILE AND EFFICACY
14:30 - 14:55
NATURAL NEUROTROPISM AS DRUG DELIVERY: LEVERAGING ZIKA VIRUS BIOLOGY TO OVERCOME THE BLOOD-BRAIN BARRIER IN GLIOBLASTOMA
Richard Rovin
UP Oncolytics

Richard Rovin

UP Oncolytics

  • Capitalizing innate neurotropism to drive targeted delivery across the BBB in glioblastoma
  • Contrasting natural-vector entry against engineered BBB-crossing tactics to reduce dose and risk
  • Charting preclinical efficacy and a translational roadmap toward first-in-human evaluation
14:55 - 15:00
Q&A SESSION ON NEUROTROPIC BBB DELIVERY IN GLIOBLASTOMA
15:00 - 15:15
FEEDBACK AND RAFFLE DRAW
15:15 - 15:30
CLOSING REMARKS

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.